戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 of transplant rejection and the treatment of lymphangioleiomyomatosis.
2 peutic approach for the treatment of TSC and lymphangioleiomyomatosis.
3 F-D dysregulation and its cellular origin in lymphangioleiomyomatosis.
4  an immunodeficient mouse xenograft model of lymphangioleiomyomatosis.
5 uberous sclerosis complex (TSC) and sporadic lymphangioleiomyomatosis.
6 uberous sclerosis complex (TSC) and sporadic lymphangioleiomyomatosis.
7 with tuberous sclerosis complex and sporadic lymphangioleiomyomatosis.
8 e individuals to both tuberous sclerosis and lymphangioleiomyomatosis.
9 sorders tuberous sclerosis complex (TSC) and lymphangioleiomyomatosis.
10 h the tuberous sclerosis complex or sporadic lymphangioleiomyomatosis.
11 h the tuberous sclerosis complex or sporadic lymphangioleiomyomatosis.
12 ut not in normal volunteers or patients with lymphangioleiomyomatosis.
13 rapy for the treatment of angiomyolipoma and lymphangioleiomyomatosis.
14 regulated in TSC-related angiomyolipomas and lymphangioleiomyomatosis.
15  factor VEGF-D are elevated significantly in lymphangioleiomyomatosis.
16 l manifestations of TSC, including pulmonary lymphangioleiomyomatosis.
17 hangioleiomyomas are common in patients with lymphangioleiomyomatosis.
18 ties are seen in a majority of patients with lymphangioleiomyomatosis.
19       The antibody HMB45 is used to diagnose lymphangioleiomyomatosis, a hyperproliferative disorder
20  associated closely with the pathogenesis of lymphangioleiomyomatosis, a rare and progressive neoplas
21              Human renal angiomyolipomas and lymphangioleiomyomatosis also express markers of EMT and
22                                    Pulmonary lymphangioleiomyomatosis and abdominal angiomyolipoma ar
23 eptor, and progesterone receptor, similar to lymphangioleiomyomatosis and angiomyolipoma.
24                         The patient also had lymphangioleiomyomatosis and lesions in the brain, skin,
25                                     Although lymphangioleiomyomatosis and pulmonary Langerhans cell h
26  interstitial lung diseases, with a focus on lymphangioleiomyomatosis and pulmonary Langerhans cell h
27 d lesions in multiple organs including lung (lymphangioleiomyomatosis) and kidney (angiomyolipoma and
28 y that was enriched for those with pulmonary lymphangioleiomyomatosis, and was therefore composed mos
29 h the tuberous sclerosis complex or sporadic lymphangioleiomyomatosis are associated with mutations i
30                                           In lymphangioleiomyomatosis, biallelic loss of TSC1/2 leads
31 ly always present in patients with pulmonary lymphangioleiomyomatosis, but the mechanisms underlying
32 plore the feasibility of targeting tumors in lymphangioleiomyomatosis by melanoma immunotherapy, we t
33 ma as well as the susceptibility of cultured lymphangioleiomyomatosis cells to melanoma reactive cyto
34 onse to HLA-matched melanocytes and cultured lymphangioleiomyomatosis cells.
35 yomatosis with serum levels in patients with lymphangioleiomyomatosis correlating with impaired lung
36 requency and volume, and in a mouse model of lymphangioleiomyomatosis, genetic downregulation of DGKA
37         Our results illuminate the basis for lymphangioleiomyomatosis growth and demonstrate the ther
38                           Some patients with lymphangioleiomyomatosis had improvement in spirometric
39 of clinical characteristics of subjects with lymphangioleiomyomatosis have been based on a limited nu
40                                    Pulmonary lymphangioleiomyomatosis is a progressive cystic lung di
41                                              Lymphangioleiomyomatosis is a rare destructive lung dise
42  age range of women afflicted with pulmonary lymphangioleiomyomatosis is broader than previously appr
43 ed in TSC-associated renal tumors, pulmonary lymphangioleiomyomatosis, kidneys from Tsc2(+/-) mice, a
44 and neural stem-like cell characteristics of lymphangioleiomyomatosis (LAM) and angiomyolipoma cells.
45                                              Lymphangioleiomyomatosis (LAM) and multifocal micronodul
46         Tuberous sclerosis complex (TSC) and lymphangioleiomyomatosis (LAM) are caused by aberrant me
47         Tuberous Sclerosis Complex (TSC) and Lymphangioleiomyomatosis (LAM) are caused by inactivatin
48                       Tumors that develop in lymphangioleiomyomatosis (LAM) as a consequence of biall
49 ated mTORC1 signaling has been implicated in lymphangioleiomyomatosis (LAM) cancer.
50  involved in the growth and proliferation of lymphangioleiomyomatosis (LAM) cells, abnormal smooth mu
51 (TSC) and in the differentiation of TSC with lymphangioleiomyomatosis (LAM) from sporadic LAM.
52             The true prevalence of pulmonary lymphangioleiomyomatosis (LAM) in patients with tuberous
53                                              Lymphangioleiomyomatosis (LAM) is a destructive lung dis
54                                              Lymphangioleiomyomatosis (LAM) is a disorder that affect
55                                              Lymphangioleiomyomatosis (LAM) is a fatal lung disease a
56                                   Rationale: Lymphangioleiomyomatosis (LAM) is a metastatic neoplasm
57                                              Lymphangioleiomyomatosis (LAM) is a multisystem disease
58                                   Rationale: Lymphangioleiomyomatosis (LAM) is a multisystem disease
59                                              Lymphangioleiomyomatosis (LAM) is a multisystem disorder
60                                              Lymphangioleiomyomatosis (LAM) is a potentially fatal lu
61                                              Lymphangioleiomyomatosis (LAM) is a progressive and ofte
62                                              Lymphangioleiomyomatosis (LAM) is a progressive cystic l
63                                              Lymphangioleiomyomatosis (LAM) is a progressive cystic l
64                                              Lymphangioleiomyomatosis (LAM) is a progressive destruct
65                                              Lymphangioleiomyomatosis (LAM) is a progressive disease
66                                              Lymphangioleiomyomatosis (LAM) is a progressive neoplast
67                                              Lymphangioleiomyomatosis (LAM) is a progressive, cystic
68                                              Lymphangioleiomyomatosis (LAM) is a rare and progressive
69                                              Lymphangioleiomyomatosis (LAM) is a rare cystic lung dis
70                                              Lymphangioleiomyomatosis (LAM) is a rare disease in whic
71                                              Lymphangioleiomyomatosis (LAM) is a rare disease of wome
72                                              Lymphangioleiomyomatosis (LAM) is a rare disease that oc
73                                              Lymphangioleiomyomatosis (LAM) is a rare disease, occurr
74                                              Lymphangioleiomyomatosis (LAM) is a rare fatal cystic lu
75                                              Lymphangioleiomyomatosis (LAM) is a rare progressive lun
76                                              Lymphangioleiomyomatosis (LAM) is a rare systemic diseas
77                                              Lymphangioleiomyomatosis (LAM) is a rare, low-grade, met
78                                              Lymphangioleiomyomatosis (LAM) is a rare, progressive lu
79                                              Lymphangioleiomyomatosis (LAM) is an interstitial lung d
80                                              Lymphangioleiomyomatosis (LAM) is an often fatal disease
81                                    Pulmonary lymphangioleiomyomatosis (LAM) is an uncommon disease re
82                                              Lymphangioleiomyomatosis (LAM) is characterized by cysti
83                                              Lymphangioleiomyomatosis (LAM) is characterized by exerc
84  were made on lung tissue from 10 women with lymphangioleiomyomatosis (LAM) to evaluate the distribut
85 e diagnosis and pharmacological treatment of lymphangioleiomyomatosis (LAM) were recently published.
86                                              Lymphangioleiomyomatosis (LAM), a cystic lung disease as
87 -based RNA therapy in a preclinical model of lymphangioleiomyomatosis (LAM), a destructive lung disea
88                                              Lymphangioleiomyomatosis (LAM), a disease that occurs pr
89                                              Lymphangioleiomyomatosis (LAM), a disorder affecting wom
90                                              Lymphangioleiomyomatosis (LAM), a multisystem disease of
91         Novel drug targets are identified in lymphangioleiomyomatosis (LAM), a rare disease in women.
92                                              Lymphangioleiomyomatosis (LAM), a rare multisystem disea
93                                              Lymphangioleiomyomatosis (LAM), a rare pulmonary disorde
94 e as a potential therapeutic target for TSC, lymphangioleiomyomatosis (LAM), and other mTORC1-hyperac
95  ECM in diseases such as atherosclerosis and lymphangioleiomyomatosis (LAM), both characterized by ex
96 cluding tuberous sclerosis complex (TSC) and lymphangioleiomyomatosis (LAM), drives B7-H3 expression
97  notably renal angiomyolipomas and pulmonary lymphangioleiomyomatosis (LAM), emerge later, placing ad
98 TSC1 or TSC2, linked to a rare lung disease, lymphangioleiomyomatosis (LAM), manifests as neoplastic
99 ncluding renal angiomyolipomas and pulmonary lymphangioleiomyomatosis (LAM).
100 yolipoma (AML) is a tumor closely related to lymphangioleiomyomatosis (LAM).
101  in tuberous sclerosis (TS) and in pulmonary lymphangioleiomyomatosis (LAM).
102 SC2 function is observed in TSC and sporadic lymphangioleiomyomatosis (LAM).
103 uberin, result in the development of TSC and lymphangioleiomyomatosis (LAM).
104 loss of their function is a cause of TSC and lymphangioleiomyomatosis (LAM).
105 ene are associated with tumor development in lymphangioleiomyomatosis (LAM).
106 k of idiopathic pulmonary fibrosis (IPF) and lymphangioleiomyomatosis (LAM).
107 oliferation of abnormal smooth muscle cells (lymphangioleiomyomatosis [LAM] cells) in LAM, we perform
108 ypsin deficiency, tuberous sclerosis complex/lymphangioleiomyomatosis, Loeys-Dietz syndrome, cystic f
109 efore, boosting immune responses to gp100 in lymphangioleiomyomatosis may offer a highly desirable tr
110 table gp100 expression; thus, tumor cells in lymphangioleiomyomatosis may process melanosomal antigen
111 sociated mouse kidney tumors, and human lung lymphangioleiomyomatosis nodules.
112 2-deficient cells and pulmonary nodules from lymphangioleiomyomatosis patients contributes to tumor g
113           In clinical isolates of PBMCs from lymphangioleiomyomatosis patients, VEGF-D expression was
114 tumor-promoting roles in the pathogenesis of lymphangioleiomyomatosis, perhaps acting as both autocri
115 od of sirolimus therapy, among patients with lymphangioleiomyomatosis, the mean forced expiratory vol
116  compared with melanoma, cells cultured from lymphangioleiomyomatosis tissue were susceptible to cyto
117       One hundred twenty-eight patients with lymphangioleiomyomatosis underwent chest and abdominopel
118 om 1998 to 2001, 243 subjects with pulmonary lymphangioleiomyomatosis were enrolled into a national r
119  diagnosis of tuberous sclerosis or sporadic lymphangioleiomyomatosis were randomly assigned, in a 2:
120        Women with tuberous sclerosis-related lymphangioleiomyomatosis were younger and had less impai
121             Among these, the most common are lymphangioleiomyomatosis, which may or may not be associ
122 SC-related skin tumors, angiomyolipomas, and lymphangioleiomyomatosis with serum levels in patients w

 
Page Top